Compare UNM & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNM | MEDP |
|---|---|---|
| Founded | 1848 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 13.4B |
| IPO Year | 1986 | 2016 |
| Metric | UNM | MEDP |
|---|---|---|
| Price | $73.21 | $543.30 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 12 |
| Target Price | $94.67 | ★ $465.18 |
| AVG Volume (30 Days) | ★ 1.2M | 268.8K |
| Earning Date | 11-03-2025 | 10-22-2025 |
| Dividend Yield | ★ 2.51% | N/A |
| EPS Growth | N/A | ★ 25.36 |
| EPS | 5.18 | ★ 14.32 |
| Revenue | ★ $13,068,000,000.00 | $2,358,373,000.00 |
| Revenue This Year | $3.91 | $21.48 |
| Revenue Next Year | $3.05 | $11.90 |
| P/E Ratio | ★ $14.17 | $37.77 |
| Revenue Growth | 2.13 | ★ 13.88 |
| 52 Week Low | $66.81 | $250.05 |
| 52 Week High | $84.48 | $626.26 |
| Indicator | UNM | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 36.21 | 34.35 |
| Support Level | $74.88 | $585.65 |
| Resistance Level | $77.30 | $626.26 |
| Average True Range (ATR) | 1.34 | 18.47 |
| MACD | -0.37 | -7.23 |
| Stochastic Oscillator | 2.99 | 12.29 |
Unum Group is a provider of group and individual income protection insurance products in the United States, the United Kingdom, Poland, and other countries. It is the domestic disability insurer, with the majority of premiums generated from employer plans. The company also offers a complementary portfolio of other insurance products, including long-term care insurance, life insurance, and employer- and employee-paid group benefits. It has the following operating business segments: Unum USA, Unum International, Closed Block, Colonial Life, and Corporate. The majority of the revenue is earned from the Unum USA segment. The firm markets its products through brokers.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.